Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Investor Presentation (August 2016)
27 slides from Aurobindo Pharma's investor presentation, August 2016
Slide 1: Investor Presentation August 2016
INVESTOR PRESENTATION August 2016
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 3: Company Overview
Company Overview Among the Top-5 listed pharmaceutical companies from India by Top 10 Therapy Segments sales(1) and market capitalization(2) Category Size (US$ Bn) APL’s presence Oncology 74.5 Well entrenched US portfolio of 403 filed ANDAs including 228 final Anti-diabetics 63.6 approved Pa
Slide 4: The Journey So Far…
The Journey So Far… Creation of a leading vertically integrated platform Acquired formulations facility Commencement of export First approval of Controlled Acquired Western European in USA and Pharmacin (now of APIs Substance formulations in commercial operations from Actavis Aurex) in Nethe
Slide 5: Strong Operational Growth
Strong Operational Growth US$ Mn FY13 CAGR FY16 Net Revenue 1,078 25% 2,128 EBITDA 164 44% 491 EBITDA 15.2% 23.1% Margin (%) PAT 54 78% 303 PAT Margin 5.0% 14.3% (%) ANDA Filed 269 398 Formulations Formulations Revenue : 57% : 79.5% Breakup API: 43% API: 20.5% 4 Note: FX rate used for conversion of
Slide 6: Our Business Segments
Our Business Segments US EU Ranked 7th* Rx supplier as per Among top 15** Gx companies IMS total prescription dispensed by sales Differentiated pipeline with new Focus markets are France, launches including injectables, Germany, Netherlands, Spain, ophthalmics , speciality products UK, Portu
Slide 7: US Business Overview
US Business Overview Aurobindo USA AuroMedics AuroLife Pharma AuroHealth Natrol Oral Rx Injectables Manufacturing / Pharma OTC Nutraceuticals R&D Cumulative ANDA Filings and Approvals Gross Sales (US$ Mn) 1000 44 50 39 45 800 45 40 41 35 600 941 30 792 30 25 564 400 20 15 200 323 10 255 5 0 0 FY13 F
Slide 8: US: Expanding Portfolio Mix Towards High-value Products
US: Expanding Portfolio Mix Towards High-value Products Portfolio mix is complemented with the introduction of high-value products Addressable Market at US$ 76.4 Bn including ~US$ 50.1 Bn for Under Review and Tentatively approved ANDAs Future pipeline to include Oncology, Hormones, Depot injections,
Slide 9: Natrol
Natrol Amongst the top 20 branded nutraceuticals companies in US Diverse Customer Base with long term relationships with key distribution and retail partners Strong customer partnerships across multiple distribution channels with growth potential within each channel R&D capabilities in new i
Slide 10: EU Business Overview
EU Business Overview France Germany Netherlands Spain UK Portugal Italy Romania Belgium India’s Leading Gx company with strong footprint in Europe Gross Sales Operations in 9 countries with full fledged sales force & support 600 26 30 infrastructure 22 500 22 25 Significant presence and positi
Slide 11: EU: Portfolio Mix Across Channels
EU: Portfolio Mix Across Channels Sales split by Channel Sales split by Therapeutic Profile Sales split by Dosage Forms Channels Gx BGx Hx TGx Germany, Spain Geographies All 9 countries 7 countries All 9 countries & Netherlands 761 (primarily 343 (predominantly 765 (including Gx # of Products 34 tab
Slide 12: ARV Business Overview
ARV Business Overview Focus on global tenders floated by Multi-Lateral Organizations like Gross Sales (US$ Mn) Global Fund, USAID/PEPFAR and Country specific MOH tenders; currently caters to 2.2 million HIV+ patients 300 15 13 250 Well integrated supply chain management services and logistics fo
Slide 13: Emerging Markets Business Overview
Emerging Markets Business Overview Focus markets include Brazil, South Africa, Ukraine and Gross Sales (US$ Mn) Mexico 150 7 8 Geographic diversification through expansion into selective 130 6 7 110 5 5 6 markets of Asia Pacific, Africa, Middle East etc 90 5 5 70 4 Opportunity to Leverage 50 77
Slide 14: The Base Business : API
The Base Business : API Gross Sales (US$ Mn) Focus on high value, specialty, small/mid-size products with a limited competition 500 43 50 Amongst the most vertically integrated generic pharma platforms 400 35 40 with API integration for around 75% of its products; offers cost 300 30 competitiven
Slide 15: Consolidated Financials
Consolidated Financials Q1 Q1 Value US$ Mn % Change FY17 FY16 Formulations 453.7 413.3 9.8% API 109.9 114.2 Formulations % of sales 80.5% 78.3% Net Operating Income 557.6 521.2 7.0% 312.6 282.3 10.7% Gross Margin 56.1% 54.2% Overheads 179.6 167.7 7.1% 133.0 114.6 16.1% EBIDTA (excl. Fx & other incom
Slide 16: Financial Performance
Financial Performance Sales (US$ Mn) EBITDA & PAT Margin (%) EPS (INR/Share) Gross Block & Fixed Asset Turnover Average ROE & ROCE % Net Debt/Eq & Net Debt/EBITDA Gross Block is calculated as Tangible Assets + Intangible Assets-Goodwill 15
Slide 17: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (INR Cr) Mar-15 Mar-16 June-16* Closing Rate1 US$ = INR 62.50 66.255 67.525 690 748 690 Fx Loan restated in INR 4,312.3 4,956.7 4,661.4 Rupee Loan 37.3 46.9 46.5 Sales Tax Deferment 54.9 41.9 0.5 Gross Debt 4,404.5 5,045.6 4,708.5 Cash Balance 450.8 805.2 1,161
Slide 18: New Business and Technology Initiatives to Support Growth
New Business and Technology Initiatives to Support Growth Peptides Manufacturing peptides from short to long chain molecules supporting mg to kg scale Highly Experienced team of scientists; developed technologies for over 10 products Three DMFs filed; work ongoing on more products Forward in
Slide 19: Key Investments for Future Growth
Key Investments for Future Growth Brownfield Expansions ► New dedicated block for lypholized vials at Unit IV (General Injectable facility), India ► New finished dosage formulations blocks at Unit VII (SEZ), India ► Substantial capacity expansion at AuroLife, USA Greenfield Projects ► Oral Solid fin
Slide 20: Way Forward
Way Forward Market share gain for existing products and introduction of new products (currently 134* ANDAs Orals under review/tentatively approved) 41* ANDA filings under review/tentatively approved for injectables along with a pipeline of Specialty Oncology, Peptides and Penem USA Expand penetratio
Slide 21: Annexure
Annexure 20
Slide 22: Sales Break-Up
Sales Break-Up FY15 FY16 FY17 US$ Mn Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1* USA 187.0 194.2 194.2 215.5 225.9 227.9 238.8 247.3 255.0 Europe 133.8 126.8 139.2 123.6 117.2 117.9 119.1 124.8 124.4 Emerging Market 23.1 25.9 21.6 22.6 27.0 25.9 27.0 26.1 29.0 ARV 37.6 23.0 54.0 42.9 46.6 41.8 46.4 48.7 45.3 Formul
Slide 23: 5 Year Financial Snapshot
5 Year Financial Snapshot Value US$ Mn FY12 FY13 FY14 FY15 FY16 Net Operating Income 961 1,078 1,344 1,986 2,128 Gross margin % of operating income 45.5% 48.9% 55.5% 54.6% 55.7% EBITDA (before Fx and other income) % to 13.2% 15.2% 26.4% 21.2% 23.1% Operating income Depreciation / Amortization 42 46
Slide 24: Filing details as on 30th June 2016
Filing details as on 30th June 2016 As at As at As at As at As at Category Approvals Mar 13 Mar 14 Mar 15 Mar 16 June 16 Formulations 269 (FA: 228, US* 269 336 376 398 403 TA:41) 1,380 Dossiers Europe** 1,341 1,542 1,756 2,224 2,327 (154 products) 168 Registrations SA** 314 334 345 376 379 (84 produ
Slide 25: Extensive Manufacturing Base with High Quality Control and Compliance
Extensive Manufacturing Base with High Quality Control and Compliance Finished Dose Formulations Active Pharma Ingredients Site Product Capabilities Site Product Capabilities Unit III Non antibiotics, ARVs / Orals Unit I CVS, CNS, Anti-Allergics, Non-Sterile Unit IV Injectables (Non-antibiotics)&Oph
Slide 26: Shareholding Pattern
Shareholding Pattern As on As on As on Group 31 Mar 15 31 Mar 16 30 June 16 Non-Promoter Holding 46.1% Promoter Group 54.0% 53.9% 53.9% FII 29.6% 27.4% 26.1% MF / Insurance 6.2% 7.2% 7.7% Other Bodies Corporates 1.6% 2.4% 3.1% Retail Investors 8.6% 9.1% 9.2% Total 100% 100% 100% Equity Shares (in Cr
Slide 27: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Deepika Gupta Padhi Phone: +91-40-66725000/5401 +91 98486 67906 Email: ir@aurobindo.com Corporate Office: Water Mark Building, Level-1, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderab
Aurobindo Pharma — Investor Presentation (August 2016) on 6ix